GlassScriptPhysician profile
An N Hoang
NPI 1194012310
$9,463.23
in general payments reported to CMS, 2019-2025
35 companies · $5,676 in 2025
The $5,676 reported for 2025 was more than what 91% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $800 · 2020: $533 · 2021: $254 · 2022: $789 · 2023: $615 · 2024: $796 · 2025: $5,676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $5,143 · Food and Beverage: $1,944.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $5,142.85 |
| Food and Beverage | $1,943.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hmu Consumables, LLC | $5,142.85 | 2025 | Dornier Medtech |
| Pfizer INC. | $714.32 | 2019-2025 | |
| Astellas Pharma US INC | $532.99 | 2019-2025 | Xtandi, Padcev |
| Janssen Biotech, INC. | $372.52 | 2019-2025 | Erleada, Akeega |
| Boston Scientific Corporation | $312.90 | 2021-2024 | Spaceoar Vue System - 10ml |
| Neotract INC. | $282.47 | 2019-2020 | |
| Myriad Genetic Laboratories, INC. | $243.05 | 2021-2025 | Prolaris |
| Merck Sharp & Dohme LLC | $229.98 | 2020-2024 | Keytruda, Welireg, Lynparza |
| Tolmar Pharmaceuticals, INC. | $197.61 | 2020-2022 | |
| Axonics, INC. | $175.95 | 2023-2024 | Axonics |
| 180 Medical, INC. | $155.33 | 2021-2025 | Gentlecath |
| Ferring Pharmaceuticals INC. | $97.47 | 2024-2025 | Adstiladrin |
| Abbvie INC. | $96.88 | 2019-2024 | |
| Endo Pharmaceuticals INC. | $91.77 | 2019-2023 | Aveed, Xiaflex |
| Progenics Pharmaceuticals, INC. | $78.18 | 2022-2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $74.52 | 2020-2023 | |
| Antares Pharma, INC. | $74.11 | 2020-2022 | |
| Tolmar, INC. | $68.30 | 2023-2025 | Eligard, Jatenzo |
| Healthtronics Stone Solutions, LLC | $48.54 | 2024 | Dornier Medtech |
| C. R. Bard, INC. & Subsidiaries | $46.87 | 2025 | |
| Procept Biorobotics Corporation | $44.86 | 2022-2023 | Aquabeam Robotic System |
| Dendreon Pharmaceuticals LLC | $36.67 | 2019 | |
| Acerus Pharmaceuticals Corporation | $35.09 | 2020-2022 | |
| Teleflex LLC | $33.85 | 2023 | Urolift |
| Olympus America INC. | $33.40 | 2025 | Itind System |
| Aytu Biopharma, INC. | $31.80 | 2019 | |
| Amgen INC. | $29.48 | 2019 | |
| Allergan, INC. | $29.47 | 2019 | |
| Coloplast Corp | $28.64 | 2022 | |
| Endo USA, INC. | $28.39 | 2025 | Aveed, Xiaflex |
| Biotissue Holdings INC. | $26.70 | 2022 | |
| Sumitomo Pharma America, INC. | $21.18 | 2023 | Orgovyx |
| Travere Therapeutics, INC. | $20.10 | 2020 | |
| Verity Pharmaceuticals INC. | $14.09 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.90 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$14,814.84 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw An Hoang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.